BELITE BIO INC. Reg.Shares(Spons.ADRs)/1 o.N.
- BID
132
- ASK
135
- 45 Units37 Units
- 07/21, 12:50:57 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
150.00%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-2.05 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 132 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 12:50:57 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 132 | 131 |
| PREV. DAY'S PRICE | 130 | (07/20) |
| CHANGE DAY BEFORE | +2.00 | 1.54 % |
| 52 WEEK HIGH / LOW | 160 (02/27) | 49.6 (07/22) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.10 | -1.09 | -2.05 | -2.77 | 0.03 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | 5,002.67 |
PRICE - BOOK RATIO | 14.75 | 13.77 | 8.17 | - | - |
PRICE - SALES RATIO | - | - | - | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3DKYL |
| ISIN | US07782B1044 |
| SYMBOL | D01 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | BELITE BIO INC.SP.ADR/1 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.00 % | 2.36 % | -6.47 % | -1.52 % | 150.00 % | - | - | -5.11 % |
| HIGH | 132.00 | 138.00 | 143.00 | 160.00 | 160.00 | - | - | 160.00 |
| LOW | 126.00 | 123.00 | 113.00 | 113.00 | 49.60 | - | - | 113.00 |
Dividende
pro Aktie
BELITE BIO INC.SP.ADR/1 does not deliver dividend information
Company profile
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.